A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT07667868 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07667868
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-01
- Primary completion
- 2027-12-31
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.